Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals
Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads. Read more
